9 results about "Coenzyme I" patented technology

Disclosed in the present invention is use of an organometallic macrocyclic compound molecule in the catalytic enhancement of the level of intracellular oxidized coenzyme I and in an anti-aging product. The organometallic macrocyclic compound molecule of the present invention enters a cell and catalyzes the conversion of reduced coenzyme I within the cell into oxidized coenzyme I, thereby enhancing the metabolic activity of the cell and prolonging the lifespan of aging animals. The organometallic macrocyclic compound molecule is applied to oxidized coenzyme I supplements, anti-aging drugs, and health care products. By means of daily oral administration, the organometallic macrocyclic compound molecule can improve the metabolic activity of the aging population, thereby maintaining their physiological health and prolonging their lifespan.

The invention belongs to the technical field of biological medicine, and particularly relates to a mycoplasma synoviae culture medium capable of improving strain titer and a preparation method of the mycoplasma synoviae culture medium. The mycoplasma synoviae culture medium comprises a basic culture medium and auxiliary components, the basic culture medium is prepared from HEPES, milk protein hydrolysate, MEM, beef heart extract powder, coenzyme I, 1% phenol red, magnesium sulfate heptahydrate, L-cysteine hydrochloride, lactose-N-tetrasaccharide, disodium clodronate and water; the auxiliary components comprise porcine serum and penicillin. According to the mycoplasma synoviae culture medium obtained by the preparation method, the passage time of the mycoplasma synoviae is shortened, and the strain titer is improved. The inactivated vaccine prepared from the chicken mycoplasma synoviae cultured by the culture medium is good in safety and immunogenicity, can effectively prevent infection of the chicken mycoplasma synoviae, and has a good application prospect.

The present application relates to the field of electroenzymatic organic synthesis, in particular to a rhodium-based catalyst and a preparation method and use thereof, the rhodium-based catalyst has the method of electrocatalytic reduction of CO2 to formic acid and the use thereof in the coupling multi-enzyme cascade reaction for producing high-value-added chemicals from CO2. The present application provides a rhodium-based catalyst ([Cp*Rh(bpy)H2O] 2+ ) and a method for simultaneously electrocatalytically reducing CO2 to formic acid and reducing oxidized coenzyme I (NAD + ) to obtain reduced coenzyme I (NADH). The above-mentioned rhodium-based catalyst effectively solves the limitation of low activity and low efficiency of enzymatic reduction of carbon dioxide to formic acid, and at the same time lays the foundation for providing necessary reducing power (NADH) for subsequent multi-enzyme cascade, and finally realizes high-added chemicals directly from CO2.

The application belongs to the technical field of biological medicine, and particularly relates to a chicken synovial mycoplasma culture medium capable of improving strain titer and a preparation method thereof. The chicken synovial mycoplasma culture medium comprises a basic culture medium and auxiliary components; the basic culture medium comprises HEPES, milk protein hydrolysate, MEM, beef heart infusion powder, coenzyme I, 1% phenol red, magnesium sulfate heptahydrate, L-cysteine hydrochloride, lacto-N-tetraose, disodium chlormethine and water; and the auxiliary components comprise pig serum and penicillin. The chicken synovial mycoplasma culture medium obtained by the preparation method shortens the passage time of chicken synovial mycoplasma and improves the strain titer. The inactivated vaccine prepared from the chicken synovial mycoplasma cultured by the culture medium has good safety and immunogenicity, can effectively prevent chicken synovial mycoplasma infection, and has a good application prospect.

The application discloses a coenzyme I crystal form and application thereof, relates to the technical field of nicotinamide adenine dinucleotide preparation, and belongs to the technical field of nicotinamide adenine dinucleotide preparation. The coenzyme I crystal form is a triclinic crystal system and has a Pl or Pl space group. The crystal lattice constant is a = 8.5894 Å, b = 8.8623 Å, c = 11.2009 Å, alpha = 109.803 DEG, beta = 90.697 DEG and gamma = 103.709 DEG. The coenzyme I crystal form provided by the application is a hydrate crystal form with high crystallinity, has good solid-state properties, the content of an effective component is obviously higher than that of a freeze-dried raw material sample, the content of maximum single substance and total impurities is obviously lower than that of the freeze-dried raw material sample, and with the prolongation of storage time, the content of maximum single substance and total impurities does not obviously increase after storage for 12 months.

The invention relates to the technical field of enzyme engineering and biology, and discloses a flavin mononucleotide reductase mutant as well as a coding gene, a recombinant vector, a recombinant strain, an enzyme preparation and application thereof. The flavin mononucleotide reductase mutant is obtained by performing at least one mutation of E43D, H145E and R203Q on an enzyme of which the amino acid sequence is as shown in SEQ ID NO. 1. The mutants and the compositions thereof can efficiently utilize flavin mononucleotide FMN and reduced coenzyme I NADH as substrates to catalyze the substrates to be converted into reduced flavin mononucleotide FMNH2 and oxidized coenzyme I NAD +. Compared with a wild enzyme, the FMNR mutant and the composition thereof provided by the invention show good FMNH2 regeneration capacity, and the catalytic efficiency of reducing FMN into FMNH2 is remarkably improved, so that a cofactor regeneration cycle system based on FMNR can realize higher production efficiency when synthesizing high-value chemicals.

The invention provides a culture method and application of mycoplasma synoviae, and belongs to the field of veterinary biological products. The mycoplasma synoviae is cultured by adopting a chicken liver cancer cell line (LMH) for the first time, and cholesterol, nicotinamide adenine dinucleotide (coenzyme I) and vitamin B12 in a certain proportion are added into a serum-free culture medium, so that high-density proliferation of the mycoplasma synoviae is realized. According to the mycoplasma synoviae prepared by adopting the culture method, the viable count and the protein content are remarkably improved, and the titer can reach 2.84 * 10 < 10 > CCU50 / mL. Meanwhile, when the strain is used for preparing inactivated vaccines, the strain has an effective prevention and control effect on poultry mycoplasma synoviae, and the challenge protection rate is larger than or equal to 90%.

The invention discloses a method for synthesizing reduced coenzyme I by a biological method, and belongs to the field of enzyme engineering. The method comprises the following steps: (1) taking nicotinamide adenine dinucleotide and glucose as substrates, and carrying out enzymatic reaction under the catalysis of a glucose dehydrogenase mutant GDH-E170K-I181S-Q252L to generate an enzymatic reaction solution; wherein the concentration of the nicotinamide adenine dinucleotide is 100-300g / L, the reaction pH is 6.5-10, the temperature is 20-40 DEG C, and the time is 10-60 minutes; and (2) sequentially carrying out anion exchange chromatography, nanofiltration concentration and crystallization purification on the enzyme catalysis reaction liquid to obtain a high-purity reduced coenzyme I product. Mild, efficient and pollution-free synthesis under high substrate concentration is realized by adopting a specific enzyme mutant, a simplified three-step purification process is combined, the HPLC purity of the final product is greater than or equal to 99%, the content is greater than 99.8%, the total yield reaches 85-95%, and the whole process is efficient, economical and suitable for large-scale production.

The application discloses a urea detection reagent, which comprises the following components: a buffer, reduced coenzyme I, alpha-ketoglutaric acid, ADP, urease, glutamate dehydrogenase, an excipient, a stabilizer, a surfactant and a preservative. The urea detection reagent has good thermal stability, is not prone to deterioration during storage, has a relatively wide effective testing range of urea, and can test a maximum concentration of urea of about 35 mmol / L.